{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:46:23Z","timestamp":1767825983874,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00345-019-02896-3","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T16:47:10Z","timestamp":1567788430000},"page":"1517-1524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC)"],"prefix":"10.1007","volume":"38","author":[{"given":"Clara","family":"Delcourt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Gemival","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois Xavier","family":"Nouhaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Gobet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Gillibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Ferlicot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Christophe","family":"Sabourin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5920-4468","authenticated-orcid":false,"given":"Christian","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"issue":"10031","key":"2896_CR1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O\u2019Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909\u20131920","journal-title":"Lancet"},{"issue":"11","key":"2896_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF, KEYNOTE-045 Investigators (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026","journal-title":"N Engl J Med"},{"issue":"7528","key":"2896_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558\u2013562","journal-title":"Nature"},{"issue":"15","key":"2896_CR4","doi-asserted-by":"publisher","first-page":"12400","DOI":"10.18632\/oncotarget.24249","volume":"9","author":"J Liu","year":"2018","unstructured":"Liu J, Zhang C, Hu J, Tian Q, Wang X, Gu H, Zhang S, Zhao D, Fan R (2018) Effectiveness of anti-PD-1\/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis. Oncotarget 9(15):12400\u201312407","journal-title":"Oncotarget"},{"issue":"3","key":"2896_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, Collette S, Oosterlinck W (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1\u00a0year versus 3\u00a0years of maintenance. Eur Urol 63(3):462\u2013472","journal-title":"Eur Urol"},{"issue":"2","key":"2896_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2015.03.029","volume":"68","author":"RJ Sylvester","year":"2015","unstructured":"Sylvester RJ (2015) Maintenance Bacillus Calmette-Gu\u00e9rin Therapy: the search for the optimum treatment schedule continues. Eur Urol 68(2):263\u2013264","journal-title":"Eur Urol"},{"issue":"4","key":"2896_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","volume":"57","author":"F Saint","year":"2001","unstructured":"Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, Debois H, Abbou CC, Chopin DK (2001) Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology 57(4):617\u2013621","journal-title":"Urology"},{"issue":"3","key":"2896_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/bju.13760","volume":"119","author":"SL Woldu","year":"2017","unstructured":"Woldu SL, Bagrodia A, Lotan Y (2017) Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 119(3):371\u2013380","journal-title":"BJU Int"},{"issue":"3","key":"2896_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz J, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275). A multicentre single-arm phase 2 trial. Lancet Oncol 18(3):312\u2013322","journal-title":"Lancet Oncol"},{"issue":"4","key":"2896_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/annonc\/mdy014","volume":"29","author":"J Adam","year":"2018","unstructured":"Adam J, Le Stang N, Roquette I, Cazes A, Badoual C, Pinot-Roussel H, Tixier L, Danel C, Damiola F, Damotte D, Penault-Liorca F, Lantuejoul S (2018) Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol 29(4):953\u2013958","journal-title":"Ann Oncol"},{"issue":"2","key":"2896_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.annpat.2018.01.007","volume":"38","author":"S Lantuejoul","year":"2018","unstructured":"Lantuejoul S, Adam J, Girard N, Duruisseaux M, Mansuet-Lupo A, Cazes A, Rouquette I, Gibault L, Garcia S, Antoine M, Vignaud JM, Galateau-Salle F, Sagan C, Badoual C, Penault-Liorca F, Damotte D (2018) PD-L1 testing in non-small cell lung carcinoma: guidelines from the PATTERN group of thoracic pathologists. Ann Pathol 38(2):110\u2013125","journal-title":"Ann Pathol"},{"issue":"4","key":"2896_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immuno therapy. Mol Cancer Ther 14(4):847\u2013856","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2896_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.urolonc.2017.01.014","volume":"35","author":"C Le Goux","year":"2017","unstructured":"Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G (2017) Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: a retrospective study. Urol Oncol 35(5):257\u2013263","journal-title":"Urol Oncol"},{"issue":"3","key":"2896_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00262-017-2093-9","volume":"67","author":"J Breyer","year":"2018","unstructured":"Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A (2018) High PDL1 mRNA expression predicts better survival of stage pT1 NMIBC patients. Cancer Immunol Immunother 67(3):403\u2013412","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2896_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ucl.2013.01.012","volume":"40","author":"JB Shah","year":"2013","unstructured":"Shah JB, Khamat AM (2013) Strategies for optimizing Bacillus Calmette Guerin. Urol Clin North Am 40(2):211\u2013218","journal-title":"Urol Clin North Am"},{"issue":"1","key":"2896_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/BLC-159001","volume":"1","author":"SP Lerner","year":"2015","unstructured":"Lerner SP, Dinney C, Kamat A, Bivalacqua TJ, Nielsen M, O\u2019Donnell M, Schoenberg MP, Steinberg G (2015) Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer 1(1):29\u201330","journal-title":"Bladder Cancer"},{"issue":"9","key":"2896_CR17","doi-asserted-by":"publisher","first-page":"34066","DOI":"10.18632\/oncotarget.26122","volume":"25","author":"A Hashizume","year":"2018","unstructured":"Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K, Wada S, Miyagi Y, Kishida T, Sasada T (2018) Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. Oncotarget. 25(9):34066\u201334078","journal-title":"Oncotarget."},{"key":"2896_CR18","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X et al (2007) PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109:1499\u20131505","journal-title":"Cancer"},{"issue":"7528","key":"2896_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563\u2013567","journal-title":"Nature"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-02896-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T23:15:27Z","timestamp":1599174927000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-02896-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2896"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-02896-3","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the respective local Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave their written informed consent to be included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}